Wells Fargo
EWTX icon

Wells Fargo’s Edgewise Therapeutics EWTX Stock Holding History

Wells Fargo’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$795K Sell
25,244
-50,198
-67% -$1.45M ﹤0.01% 3871
2025
Q4 		$1.87M Buy
75,442
+33,246
+79% +$667K ﹤0.01% 3497
2025
Q3 		$684K Buy
42,196
+3,812
+10% +$54.1K ﹤0.01% 4081
2025
Q2 		$503K Buy
38,384
+3,226
+9% +$46.5K ﹤0.01% 4147
2025
Q1 		$773K Buy
35,158
+1,240
+4% +$32.5K ﹤0.01% 3806
2024
Q4 		$906K Buy
33,918
+11,561
+52% +$368K ﹤0.01% 3779
2024
Q3 		$597K Sell
22,357
-884
-4% -$17.6K ﹤0.01% 3876
2024
Q2 		$419K Buy
23,241
+2,810
+14% +$49K ﹤0.01% 4021
2024
Q1 		$373K Buy
20,431
+7,255
+55% +$115K ﹤0.01% 4075
2023
Q4 		$144K Buy
13,176
+2,602
+25% +$18.3K ﹤0.01% 4673
2023
Q3 		$60.6K Sell
10,574
-5,710
-35% -$38.8K ﹤0.01% 5077
2023
Q2 		$126K Buy
16,284
+9,527
+141% +$80.4K ﹤0.01% 4888
2023
Q1 		$45.1K Buy
+6,757
New +$62.6K ﹤0.01% 5214
2022
Q4 		– Sell
-59
Closed -$1K – 7531
2022
Q3 		$1K Sell
59
-197
-77% -$1.99K ﹤0.01% 6328
2022
Q2 		$2K Sell
256
-3,676
-93% -$27.8K ﹤0.01% 6311
2022
Q1 		$38K Sell
3,932
-13,920
-78% -$179K ﹤0.01% 5777
2021
Q4 		$273K Buy
+17,852
New +$321K ﹤0.01% 5089

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wells Fargo's EWTX Position: Q1 2026 in Review

Wells Fargo reduced its Edgewise Therapeutics (EWTX) stake by 67% in Q1 2026, selling an estimated $1.45M and leaving 25,244 shares worth $795K. The position accounts for ﹤0.01% of the portfolio, ranked #3871.

Wells Fargo first reported a position in EWTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.87M in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Wells Fargo held 25,244 shares of Edgewise Therapeutics worth $795K as of Q1 2026.
  • Wells Fargo sold 50,198 Edgewise Therapeutics shares in Q1 2026, an estimated $1.45M.
  • Edgewise Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3871 holding.
  • Wells Fargo first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Wells Fargo's Edgewise Therapeutics position peaked at $1.87M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.